Energy Efficiency and Renewable Energy Contracting
Client Alert | 1 min read | 05.28.09
In Doing Business with the Government in 2009: New Opportunities for Energy Efficiency and Renewable Energy Contracting in the May 2009 issue of Bloomberg Sustainable Energy Law Reports, J. Catherine Kunz and Steve McBrady of Crowell & Moring examine the federal government's unprecedented investment in renewable energy infrastructure and related research and development via the recently passed American Recovery and Reinvestment Act (ARRA). This substantial federal commitment will generate increased business opportunities for government contractors in energy efficient technology, renewable energy, energy infrastructure, and related fields; however, contractors must be aware that contracting under the ARRA will also require compliance with new regulations and a number of new oversight and reporting requirements.
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
